Morgan Stanley Maintains Overweight on Attovia Therapeutics, Raises Price Target to $40
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Judah Frommer maintains Attovia Therapeutics (NASDAQ:ATTO) with a Overweight and raises the price target from $39 to $40.
Morgan Stanley analyst Judah Frommer maintains Attovia Therapeutics (NASDAQ:ATTO) with a Overweight and raises the price target from $39 to $40.